AzTrials
AzTrials

Peripheral Arterial DiseasePhase 1NCT05036213

The Effects of Oral Inorganic Nitrate Supplementation on Lower Limb Perfusion During Exercise in Patients With PAD

A Phase 1 study testing BEET IT - Concentrate Beet root juice and BEET IT - Concentrate Beet root juice (nitrate depleted) in people with Peripheral Arterial Disease and Peripheral Vascular Diseases, run by University of Virginia at 1 site in United States.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Peripheral arterial disease (PAD) is a highly prevalent and costly condition. Intermittent claudication (IC), defined as ischemic leg pain that occurs with walking, results in functional impairment, reduced daily physical activity, and a lower quality of life. Read more about this study

Who is it for?
Ages 40 to 80 years
What is being tested?
BEET IT - Concentrate Beet root juice and BEET IT - Concentrate Beet root juice (nitrate depleted)
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
28 participants
Where
1 siteUnited States
Study dates
1 Feb 2020to Dec 2024
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 40 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • - History of stable intermittent claudication for 3 or more months, and an Ankle-brachial index test (ABI) <0.9 at rest.
  • Symptomatic PAD (claudication or critical limb ischemia)

Who cannot join

  • - Limb threatening ischemia, including rest pain and/or gangrene; impending limb loss or chronic osteomyelitis.
  • Lower extremity vascular surgery, angioplasty or lumbar sympathectomy within 3 months of enrollment;
  • severe peripheral neuropathy or any condition other than PAD that limits walking such as unstable angina;
  • history of significant left main or three vessel coronary artery disease (>70% stenosis, unprotected by grafts) or recent myocardial infarction (6 weeks);
  • chest pain during treadmill exercise which appears before the onset of claudication,
  • chronic renal failure with an eGRF<30; Type 1diabetes mellitus, a BMI>40, and a HbA1c>8.5%. Refusal to give or inability to give informed consent. Pregnancy (Self-reported).

Trial locations and contacts

1 site in 1 country.

Casey C Derella, PhD contact

434-243-8677

bxg7vn@virginia.edu

United States1 site, 1 recruiting
  • University of Virginia

    Charlottesville, Virginia, 22903

    Jason D. Allen, PhD, 434-243-0736, ja6af@virginia.edu

    Christopher M. Kramer, MD

    Recruiting

Other trials in United States

About this study

Official title: The Effects of Oral Inorganic Nitrate Supplementation on Lower Limb Perfusion and Metabolism During Exercise in Patients With Peripheral Arterial Disease (PAD)

Peripheral arterial disease (PAD) is a highly prevalent and costly condition. Intermittent claudication (IC), defined as ischemic leg pain that occurs with walking, results in functional impairment, reduced daily physical activity, and a lower quality of life. Although the mechanisms contributing to functional impairment are not fully delineated, current evidence suggests that the uncoupling of skeletal muscle cellular metabolism from tissue perfusion may be responsible for exercise intolerance. We have previously shown increases in plasma inorganic nitrite, via oral nitrate, produced clinically significant increases exercise performance in patients with PAD+IC.

The hypothesis of this proposal is in patients with PAD+IC, 3-6 days of oral dietary nitrate consumption (in the form of concentrated beetroot juice) will produce a greater tissue perfusion, oxygen delivery, and enhanced muscle metabolism in comparison to placebo. This will translate into an increase in physical performance in both muscle specific plantar flexion exercise and treadmill measures of pain free ambulation. In order to test this hypothesis, we will recruit 10 patients PAD+IC in a randomized, double-blind, placebo controlled, cross over design.

Read the detailed description

Peripheral Arterial Disease (PAD) is characterised by blockages (occlusion or stenosis) in the large arteries of the lower limbs. It is estimated that worldwide prevalence of PAD has increased by 23.5% in the last decade and now affects 202 million people. PAD prevalence increases with age from 5% of 45-49-year-old up to 19% in those >70years old and smoking and diabetes are causative factors. PAD is vastly understudied in comparison to cardiac or cerebrovascular diseases. Intermittent claudication (IC) is the major clinical manifestation of PAD and occurs when arterial occlusive disease reduces blood flow to the peripheral vasculature during exercise. Among subjects with intermittent claudication from PAD, 1/3rd have pain during light activity at home and an additional 1/3rd have pain walking a short distance (one block). These patients suffer from a markedly impaired quality of life and a high perception of disability. Increased pain free ambulation is a primary goal of therapy for PAD as this is related to improved quality of life.

Although the ankle-brachial systolic blood pressure index (ABI) and limb blood flow testing are used to diagnose PAD, most research studies fail to show a relationship between these measures and functional capacity. Confounding the understanding of this disease is that surgical revascularization, which improves blood flow, does not normalize exercise performance and ambulation can be increased without changes in hemodynamics. Professor Allen (PI) has previously shown increases in peak hyperemic leg blood flow with exercise training but failed to find a relationship between these changes and increases in claudication onset time (COT) and peak walk time (PWT). Professors Allen and Annex (Chief UVa Health System - Cardiovascular Medicine) have also shown increases in gastrocnemius capillary density following exercise training and a correlation with VO2peak. This suggests, in the presence of conduit vessel stenosis, patients become more reliant on the microvasculature to distribute available blood and oxygen to working tissues more efficiently.

Nitric Oxide (NO) is produced by the vascular endothelium and plays an important role in vasodilation, flow regulation and platelet function. Disruptions in the production of NO have been implicated in the pathogenesis of vascular disease. It was originally believed that the bioactivity of NO was limited both temporally and spatially to the proximity of the vascular endothelium where it was produced. It is now clear that several protected NO-derived species may be transported through the vasculature to be released at critical areas of the circulation, where it can influence macro- and micro-vascular tone and possibly vasculopathy. Under normal conditions, this endocrine-like role is precisely controlled: whereby during normoxia NO is conserved but under hypoxic conditions NO is liberated and can initiate vasodilation. One potential therapeutic option involves the conversion of inorganic nitrate (NO3-) and nitrite (NO2-) anions into NO (and other bioactive species). This is an attractive approach, as it is biologically distinct from endothelial-NO synthase and can be achieved easily via oral administration. Inorganic NO3- is abundant in green leafy vegetables, beets, celery, lettuce, radishes and spinach.

We were the first group to demonstrate acute increases in plasma NO2- concentration (using beetroot juice containing 9mM NO3-), and increased walking performance in subjects with PAD+IC. COT increased by 18% (32sec) and PWT by 17% (65sec). This is a clinically meaningful and statistically significant increase for a disease state characterized by reduced physical function and quality of life. There were no changes in ABI or endothelial function suggesting no increase in endogenous vascular NO. The increases in performance were accompanied by a reduction in fractional oxygen extraction at the working tissues, measured by near infra-red spectroscopy (NIRS) suggesting increased perfusion to working tissues.

We have subsequently demonstrated that chronic dosing in combination with 36 sessions of exercise training (EX+BR) also generated significant increases in pain free ambulation (COT) and like-wise reductions in deoxyhemoglobin during exercise, when compared to an identical exercise regimen coupled with placebo.

Unfortunately, while Near Infrared Spectroscopy (NIRS) data during a physiological challenge is indicative, it is also relatively imprecise -NIRS measures only relative oxygenation/deoxygenation for the whole tissue-bed. A much more precise non-invasive approach has been developed by Professor Christopher Kramer (UVa Health System - Cardiovascular Medicine, Noninvasive Cardiovascular Imaging) and Professor Craig H. Meyer (Department of Biomedical Engineering) which utilizes Pulsed Arterial Spin Labelling (PASL) coupled with a cuff occlusion or plantar flexion exercise stress test developed by Professor Arthur Weltman (UVa - Department of Kinesiology). This allows for the creation of tissue perfusion maps and differentiation between specific gastrocnemius muscle compartments in a spatial and temporally resolved fashion. Additionally, we will employ Creatine Exchange Saturation transfer (CrCEST) to measure PCr recovery kinetics after exhaustive exercise or until subjects symptoms limit their exercise tolerance.

These techniques in combination will allow us to differentiate deficits in tissue perfusion and metabolism (mitochondrial function) for specific compartments of the gastrocnemius muscle before and after intervention. The sensitivity to detect changes following inorganic nitrate (BR) supplementation was previously demonstrated in healthy subjects during severe exhaustive exercise (which creates hypoxic conditions in the tissue bed analogous to those in patients with PAD+IC during mild exercise). The participants on BR showed an increase in exercise tolerance and a reduction in PCr depletion, suggesting changes in muscle metabolism/function. However, the effect of BR on the metabolic responses and tissue perfusion during exhaustive exercise in PAD patients has not been investigated to date.

The hypothesis of this proposal is in patients with PAD+IC, 3-6 days of oral dietary nitrate consumption (in the form of concentrated BR) will produce a greater tissue perfusion, oxygen delivery, and enhanced muscle metabolism in comparison to placebo (PL). This will translate into an increase in physical performance in both muscle specific planter flexion exercise and treadmill measures of pain free ambulation. In order to test this hypothesis, the following specific aims will recruit 24 PAD+IC patients in a randomized, double-blind, placebo controlled, cross over design.

Aim 1. To determine between treatment differences (BR v PL) in phosphocreatine recovery time constant (PCr) measured by Creatine chemical Exchange Saturation Transfer (CrCREST).

Aim 2. To determine between treatment differences (BR v PL) in peak exercise, maximal hyperemia in different lower limb compartments (anterior, lateral, gastrocnemius, soleus and deep compartments) by Pulsed Arterial Spin Labelling (PASL).

Aim 3. To determine relations in between treatment changes in walking performance COT and PWT and lower limb compartmental perfusion characteristics (Aim 2) and phosphocreatine recover kinetics (Aim 1).

Being tested
BEET IT - Concentrate Beet root juice, BEET IT - Concentrate Beet root juice (nitrate depleted)
Keywords
PAD, nitrate, nitric oxide
Medical subject headings
Peripheral Arterial Disease, Peripheral Vascular Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • BEET IT - Concentrate Beet root juiceDrug

    Also called Dietary Nitrate supplementation (nitrate rich)

    Each bottle contains 75ml of concentrated beetroot juice with approximately 6.2mmol of inorganic nitrate. The product is provided by BEET IT, James White Drinks, Ipswich, UK.

  • BEET IT - Concentrate Beet root juice (nitrate depleted)Drug

    Also called Dietary Nitrate supplementation (nitrate depleted)

    Each bottle contains 75ml of concentrated beetroot juice with depleted nitrate, thus, no inorganic nitrate is found in thisbeverage. The product is also provided by BEET IT, James White Drinks, Ipswich, UK.

Study groups in NCT05036213
Study groupRoleWhat they receive
Dietary nitrateActive comparatorThe active treatment, beetroot juice (BEET IT, James White Drinks, Ipswich, UK), contains 6.2mmol of inorganic nitrate. Participants will continue supplementation until they complete all testing visits.
Receives: Drug: BEET IT - Concentrate Beet root juice
concentrated beet root juice with depleted nitrate contentPlacebo comparatorThe placebo treatment is also beetroot juice provide by the same company (BEET IT, James White Drinks, Ipswich, UK), but it does not contain any inorganic nitrate. Participants will continue supplementation until they complete all testing visits.
Receives: Drug: BEET IT - Concentrate Beet root juice (nitrate depleted)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Phosphocreatine kinetics after maximal exercise

    The primary outcomes to be analyzed will be treatment differences (BR v PL) in phosphocreatine recovery time constant (PCr) measured by Creatine chemical Exchange Saturation Transfer (CrCREST).

    The subjects will be positioned within the scanner feet first with the calf at the isocenter of the magnet and a flexible phased array coil will be positioned and wrapped around the calf of interest. Imaging of calf muscle energetics using creatine chemical exchange saturation transfer (CrCEST, no contrast agent used) will be performed after pedal ergometry until exhaustion or limiting symptoms

    Measured: After a minimum of 3 days of supplementation with either Placebo or nitrate rich beverage.

Secondary outcomes (5)
  1. Maximal hyperemia in different lower limb compartments

    At the Prisma 3T scanner at Fontaine, subjects will be positioned within the scanner feet first with the calf at the isocenter of the magnet and a flexible phased array coil will be positioned and wrapped around the calf of interest. Subjects to complete plantar flexion ergometry to exhaustion or claudication. Imaging of calf muscle perfusion by arterial spin labeling (ASL, no contrast agent used) will be performed after pedal ergometry until exhaustion or limiting symptoms.

    Measured: After a minimum of 3 days of supplementation with either Placebo or nitrate rich beverage.

  2. Peak exercise

    Subjects will be tested on two different occasions (PL vs Beet root juice) for how long they can walk (in seconds) on a treadmill. The treadmill walking test is designed specifically for a claudication-limited population (i.e. the Gardner protocol). During this walking test the speed is maintain at 2mph with a 2%-grade increase every 2 minutes.

    Measured: After a minimum of 3 days of supplementation with either Placebo or nitrate rich beverage.

  3. Claudication Onset Time

    During the treadmill exercise protocol subjects will report when they start to feel pain in their lower limbs (or the affect leg).

    Measured: After a minimum of 3 days of supplementation with either Placebo or nitrate rich beverage.

  4. Vascular Function - Brachial Flow Mediated Dilation

    A high-resolution ultrasound will be used to capture images of the brachial artery at baseline, during 5 minutes of forearm occlusion, and for two minutes (with r-wave trigger) following occlusion cuff release. These data points will be utilized to calculate the percentage of change in brachial artery diameter following reactive hyperemia (occlusion release).

    Measured: After a minimum of 3 days of supplementation with either Placebo or nitrate rich beverage.

  5. Vascular stiffness

    Vascular stiffness will be assessed by measures of pulse wave velocity using applanation tonometry (SphygmoCor EXCEL system V1). The measures provided by PWA include: central systolic pressure (mmHg); central pulse pressure (PP) mmHg; augmentation pressure (AP) and augmentation index (AIx).

    Pulse wave velocity is measured via a simultaneous comparison of the carotid and femoral arterial pulses. A thigh cuff will be placed around the patient's upper thigh which acts to measure the femoral pulse via pulsations, whilst simultaneously a tonometer will be used to assess the carotid pulse. Higher pulse wave velocities from the carotid to femoral arteries indicates higher aortic stiffness.

    Measured: After a minimum of 3 days of supplementation with either Placebo or nitrate rich beverage.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Sep 2021
  2. Study start1 Feb 2020
  3. Primary completionDec 2024 (estimated)
  4. Study completionDec 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Crossover
Model description
This is a randomized, double-blind, placebo-controlled, cross-over design. This means that all subjects will complete both supplementation phases in a randomized order.
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
28 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05036213
Sponsor's protocol ID
21774
Status last verified
Nov 2023
First submitted
1 Sep 2021
Last updated
29 Nov 2023
Results posted
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: Individual participant data that underlie the results reported in this RCT, after deidentification (text, tables, figures, and appendices).

Publications

  • Isbell DC, Epstein FH, Zhong X, DiMaria JM, Berr SS, Meyer CH, Rogers WJ, Harthun NL, Hagspiel KD, Weltman A, Kramer CM. Calf muscle perfusion at peak exercise in peripheral arterial disease: measurement by first-pass contrast-enhanced magnetic resonance imaging. J Magn Reson Imaging. 2007 May;25(5):1013-20. doi: 10.1002/jmri.20899.

    PubMed 17410566
  • Isbell DC, Berr SS, Toledano AY, Epstein FH, Meyer CH, Rogers WJ, Harthun NL, Hagspiel KD, Weltman A, Kramer CM. Delayed calf muscle phosphocreatine recovery after exercise identifies peripheral arterial disease. J Am Coll Cardiol. 2006 Jun 6;47(11):2289-95. doi: 10.1016/j.jacc.2005.12.069. Epub 2006 May 15.

    PubMed 16750698
  • Lopez D, Pollak AW, Meyer CH, Epstein FH, Zhao L, Pesch AJ, Jiji R, Kay JR, DiMaria JM, Christopher JM, Kramer CM. Arterial spin labeling perfusion cardiovascular magnetic resonance of the calf in peripheral arterial disease: cuff occlusion hyperemia vs exercise. J Cardiovasc Magn Reson. 2015 Feb 22;17(1):23. doi: 10.1186/s12968-015-0128-y.

    PubMed 25890198
  • Kenjale AA, Ham KL, Stabler T, Robbins JL, Johnson JL, Vanbruggen M, Privette G, Yim E, Kraus WE, Allen JD. Dietary nitrate supplementation enhances exercise performance in peripheral arterial disease. J Appl Physiol (1985). 2011 Jun;110(6):1582-91. doi: 10.1152/japplphysiol.00071.2011. Epub 2011 Mar 31.

    PubMed 21454745

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing BEET IT - Concentrate Beet root juice and BEET IT - Concentrate Beet root juice (nitrate depleted) in people with Peripheral Arterial Disease and Peripheral Vascular Diseases, run by University of Virginia at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 29 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Casey C Derella, PhD (434-243-8677, bxg7vn@virginia.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Phosphocreatine kinetics after maximal exercise (time frame: After a minimum of 3 days of supplementation with either Placebo or nitrate rich beverage.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05036213, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Nov 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in